Literature DB >> 2142747

Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.

K Tobal1, A Pagliuca, B Bhatt, N Bailey, D M Layton, G J Mufti.   

Abstract

We studied 41 patients with myelodysplastic syndromes or acute myeloid leukemia to assess the presence of point mutations in the human FMS gene (M-CSF receptor). Using the polymerase chain reaction and hybridization of oligonucleotide probes to the amplified sequences, we have detected mutations in eight of 41 patients, at codons 301 and 969. In vitro work has highlighted mutations at these codons as being oncogenic. We now report the detection of potentially activating mutations of the human FMS gene in vivo. The consequence of these mutations in the multistep pathogenesis of myeloid malignancy and their relevance to prognosis remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142747

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage.

Authors:  Irina Ushach; Albert Zlotnik
Journal:  J Leukoc Biol       Date:  2016-06-28       Impact factor: 4.962

2.  The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor.

Authors:  D E Zhang; C J Hetherington; H M Chen; D G Tenen
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

3.  FMS hemizygosity in myeloid dysplasia and acute myeloid leukemia with chromosomal aberration del(5)(q) demonstrated by polymerase chain reaction.

Authors:  M Pfeilstöcker; R Grill; E Koller; O Krieger; E Pittermann; H Karlic
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

4.  Relation of in vitro growth characteristics to cytogenetics and treatment outcome in acute myeloid leukemia: prognostic significance in patients with a normal karyotype.

Authors:  Andrea Berer; Birgit Kainz; Ulrich Jäger; Eva Jäger; Susanna Stengg; Berthold Streubel; Christa Fonatsch; Gerlinde Mitterbauer; Klaus Lechner; Klaus Geissler; Leopold Ohler
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

5.  A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.

Authors:  Ting-lei Gu; Thomas Mercher; Jeffrey W Tyner; Valerie L Goss; Denise K Walters; Melanie G Cornejo; Cynthia Reeves; Lana Popova; Kimberly Lee; Michael C Heinrich; John Rush; Masanori Daibata; Isao Miyoshi; D Gary Gilliland; Brian J Druker; Roberto D Polakiewicz
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

Review 6.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

7.  Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases.

Authors:  Andrew J Shih; Shannon E Telesco; Ravi Radhakrishnan
Journal:  Cancers (Basel)       Date:  2011-03       Impact factor: 6.639

8.  Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Authors:  D Raepple; F von Lintig; T Zemojtel; M Duchniewicz; A Jung; M Lübbert; G R Boss; J S Scheele
Journal:  Ann Hematol       Date:  2008-09-11       Impact factor: 3.673

9.  Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain.

Authors:  T van Daalen Wetters; S A Hawkins; M F Roussel; C J Sherr
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

Review 10.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.